- Synthetic Heterocyclic Derivatives as Kinase Inhibitors Tested for the Treatment of Neuroblastoma
Francesca Musumeci et al, 2021, Molecules CrossRef - PAK4 in cancer development: Emerging player and therapeutic opportunities
Yixi Yuan et al, 2022, Cancer Letters CrossRef - The Combined Use of Orf Virus and PAK4 Inhibitor Exerts Anti-tumor Effect in Breast Cancer
Hao Deng et al, 2022, Frontiers in Microbiology CrossRef - MI‑773, a breaker of the MDM2/p53 axis, exhibits anticancer effects in neuroblastoma via downregulation of INSM1
Yan-Ling Chen et al, 2021, Oncology Letters CrossRef - ARV-825 Demonstrates Antitumor Activity in Gastric Cancer via MYC-Targets and G2M-Checkpoint Signaling Pathways
Xinmei Liao et al, 2021, Frontiers in Oncology CrossRef - Combination of PAKs inhibitors IPA-3 and PF-3758309 effectively suppresses colon carcinoma cell growth by perturbing DNA damage response
Muzaffer Dukel et al, 2023, International Journal of Radiation Biology CrossRef - Biological role of the PAK4 signaling pathway: A prospective therapeutic target for multivarious cancers
Md. Mozibullah et al, 2023, Arabian Journal of Chemistry CrossRef - BRD4 inhibitor GNE987 exerts anti-cancer effects by targeting super-enhancers in neuroblastoma
Yan-Ling Chen et al, 2022, Cell & Bioscience CrossRef - The Use of Nanomedicine to Target Signaling by the PAK Kinases for Disease Treatment
Yiling Wang et al, 2021, Cells CrossRef - p21-activated kinase 4 as a switch between caspase-8 apoptosis and NF-κB survival signals in response to TNF-α in hepatocarcinoma cells
Qing Li et al, 2018, Biochemical and Biophysical Research Communications CrossRef - miR-135b-5p promotes gastric cancer progression by targeting CMTM3
Mingdong Lu et al, 2017, International Journal of Oncology CrossRef - PROTAC Bromodomain Inhibitor ARV-825 Displays Anti-Tumor Activity in Neuroblastoma by Repressing Expression of MYCN or c-Myc
Zhiheng Li et al, 2020, Frontiers in Oncology CrossRef - Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials
Ann Lin et al, 2019, Science Translational Medicine CrossRef - miR-27a promotion resulting from silencing of HDAC3 facilitates the recovery of spinal cord injury by inhibiting PAK6 expression in rats
Qingzhong Zhou et al, 2020, Life Sciences CrossRef